Multi-nutrient supplement improves hormone ratio associated with cancer risk by unknown
Bazzan et al. Journal of Translational Medicine 2013, 11:252
http://www.translational-medicine.com/content/11/1/252RESEARCH Open AccessMulti-nutrient supplement improves hormone
ratio associated with cancer risk
Anthony J Bazzan, George P Zabrecky and Andrew B Newberg*Abstract
Background: Gynecological cancers are among the most common in women and are directly related to a variety
of hormonal factors. One potential risk factor associated with developing a gynecological malignancy is the ratio of
two hormone metabolites, 2-Hydroxyestrone (2-HE) and 16alpha-Hydroxyestrone (16alpha-HE). A number of
botanical constituents such as indoles, flavonoids, and resveratrol have been shown to have a favorable effect on
the metabolic pathways that affect this ratio. The present study was designed to evaluate if a multi-nutrient
supplement containing targeted botanical constituents would affect the 2-HE/16 alpha-HE ratio in middle-aged
women.
Methods: A retrospective analysis was performed on 76 female patients (mean age 54 years) who received 2-HE/16
alpha-HE ratio assessments at two separate time points. The ratio assessment was part of standard care for women
who presented with risk indicators associated with a high proliferative state. All patients who completed pre and
post assessments were included. Sixty-five of the patients received a multi-nutrient supplement, Lucentia Peak®,
during the study period. Eleven patients chose not to take the supplement, but did receive ratio assessments at
similar time points as the treatment group, allowing for between group comparisons. Paired t-tests were used to
compare the changes in the 2-HE and 16alpha-HE measures as well as their ratio, both within groups and between
groups.
Results: The results demonstrated a significant increase in the 2-HE/16alpha-HE ratio in the treated group (pre 0.38
to post 0.57, p<0.0001), and was significantly different (p=0.02) compared to the change in the control group
(pre 0.65 to post 0.64). This change appears to be mediated primarily by an increase in the 2-HE level.
Individually, 54 patients given Lucentia Peak® had increased ratios while 11 patients had a decrease. In the
control group, 3 patients had an increase in their ratio and 8 patients had a decrease.
Conclusions: The results demonstrated that women receiving the Lucentia Peak® multi-nutrient supplement
had significant increases in their 2-HE:16alpha-HE ratio, which appears to be mediated primarily by increasing
the 2-HE levels. These results suggest further research on phytonutrients that might positively affect estrogen
metabolism is warranted.
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Table 1 Supplement contents given as the amount of
compound in one serving (4 capsules)
Calcium D- Glucarate 150 mg
Magnesium Citrate 50 mg
Resveratrol 20 mg
Poly-ionic Saccharide Complex 175 mg
(Zehntose™)
Red Clover Extract 125 mg
(Standardized to 8% isoflavone)
BioResponse DIM® Complex 75 mg
(Diindolylmethane)
Epimedium (Stem and Leaf Extract) 250 mg
(Standardized to 10% Icariin)
Eucommia Bark Extract 100 mg
(Standardized to 40% Chlorogenic Acid)
Passion Flower (Leaf) Extract 75 mg
(Standardized to 3.5% as Isovitexin)
Suma (Root) Extract 60 mg
Damiana (Leaf) Extract 40 mg
Black Currant Extract 120 mg
White Button Mushroom 100 mg
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Gynecological cancers are among the most common in
women and are directly related to a variety of hormones.
One potential risk for developing a gynecological malig-
nancy is the relative ratio of two hormone metabolites,
2-Hydroxyestrone (2-HE) and 16alpha-Hydroxyestrone
(16alpha-HE). Several early studies showed no significant
difference in this 2-HE/16alpha-HE ratio between women
currently with or without breast cancer [1-3]. However,
more recent studies, including a longitudinal evaluation,
showed that a higher ratio lowers the risk of developing
future gynecological cancers [4,5]. Approaches that posi-
tively affect this ratio could have important implications
for patients at risk of developing gynecological cancers.
Several naturally occurring, plant-derived compounds
have been investigated for increasing the 2-HE/16alpha-
HE ratio. Indoles may help increase this ratio; in particular,
indole-3-carbinol (I3C), a natural compound derived
by hydrolysis from glycobrassicin produced in crucifer-
ous vegetables such as cabbage, broccoli, and Brussels
sprouts, and its natural diindole condensation product
3-3’-diindolylmethane (DIM) [6]. Several studies pro-
vide evidence that both of these indoles can improve
the 2-HE/16alpha-HE ratio when given in the appro-
priate dose [7]. DIM, can induce estrogenic responses
through a ligand-independent activation of estrogen
receptors or disrupt estrogen responsiveness through its
interaction with the aryl hydrocarbon receptor [8,9].
Bioflavonoids have also been found to have anti-
proliferative properties [10-12] that are mediated by sev-
eral mechanisms. For example, bioflavonoids can interfere
with several different free radical–producing systems
and can also increase the function of the endogenous
antioxidants [13] and can also inhibit cell proliferation
and angiogenesis [14,15]. However, it is not clear whether
bioflavonoids specifically alter the 2-HE/16alpha-HE ratio.
Another compound, resveratrol, has been shown to
regulate estrogen effects also possibly conferring a
beneficial effect with regard to the development of ma-
lignancy [16-18]. Several other herbal supplements
might have beneficial effects as well. For example,
icariin, a prenyl flavonoid derivative from Epimedium
Genus has been shown to induce cell cycle arrest in
breast cancer cells [19] and also has estrogenic effects
[20]. Red clover has been shown to possess antioxidant
and antiinflammatory activities, as well as inhibit angio-
genesis and displaying anti-cancer properties [21]. Black
currant extracts have been shown to have a variety of
phytochemicals that have anti-proliferative effects via
multiple cellular mechanisms [22].
These studies and others have led to the development
of multi-nutrient supplements that blend compounds
such as these to help improve the hormonal ratio and
reduce the proliferative state. The goal of the presentstudy was to retrospectively evaluate the effects of a
multi-nutrient supplement designed for this purpose.
Methods
All patients in a university hospital out-patient setting
who received 2-HE/16alpha-HE assessments at two dis-
tinct time points between 2010 and 2012 were included
in this study. We retrospectively evaluated the hormone
metabolism ratio of 65 patients (mean age 54±9 years)
receiving the multi-nutrient supplement, Lucentia Peak®,
for dietary support and preventive care. Since this was a
retrospective evaluation of existing clinical data, this
study was deemed exempt from review by the Institu-
tion Review Board (IRB) at Thomas Jefferson University
and was administratively approved as per IRB guidelines.
The supplement contains a combination of resveratrol,
diindolylmethane, epimedium, eucommia, passion flower,
suma, damiana, red clover, black currant extract, white
button mushroom, and also vitamin E and C, calcium, and
magnesium. The exact contents are provided in Table 1.
We compared these results to 11 patients (mean age 54±5
years) who chose not to take the supplement, but were
willing to receive a follow-up ratio assessment as part of
overall clinical care. This formed the control group for
the comparison. The mean duration of treatment was
196±175 days. The mean time between evaluations for
the treatment group was 288±343 days and for the con-
trol group was 891±531 days. A paired t-test was used
to compare the changes in the 2-HE and 16alpha-HE
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between the ratio changes for the two groups was also
performed. Serum measures of the 2-HE/16alpha-HE
ratio were used in this study (27).
Results
The results are shown in Table 2 and demonstrate a
significant increase in the 2-HE levels and in the 2-HE/
16alpha-HE ratio in the treated group (p < 0.0001), but
no change to either of these measures in the untreated
group. On an individual basis, 54 patients given Lucentia
Peak had an increase in their 2-HE/16alpha-HE ratio (i.e.
improvement), while 11 patients had a decrease (wors-
ening). In the control group, 3 patients had an increase
in their 2-HE/16alpha-HE ratio and 8 patients had a de-
crease. Overall, the treated group had a mean increase
in the 2-HE/16alpha-HE ratio of 18 points (50%) while
the control group had a decrease of 1 point. This differ-
ence between the treated and control group change in
the ratio was statistically significant (p=0.02) based on a
t-test comparing the change between the treated and
control groups.
Discussion
The results from the current study demonstrated that
women who received the Lucentia Peak® multi-nutrient
supplement had substantial improvements in their 2-HE:
16alpha-HE ratio, and this appears to be mediated primar-
ily by increasing the 2-HE levels. These results were com-
parable to another study that gave indole-3-carbinol to
women at high risk for breast cancer [16]. In that study,
17 women were evaluated and treated with increasing
doses of indole-3-carbinol for 4 weeks. Patients receiving
800 mg per day demonstrated elevation in the CYP1A2
activity, which mirrored a 66% increase in the urinary 2-
HE/16alpha-HE ratio in response to I3C. In that study, the
maximal increase was observed with the 400 mg daily of
I3C, with no further increase found at 800 mg daily. In a
related study, Wong et al. demonstrated in 57 women that
300 mg per day of I3C significantly increased the 2-HE/
16alpha-HE ratio [7]. Additionally, the other indole, DIM
has antitumorogenesis effects [23] in breast cancer. And a
small placebo controlled study of 19 women given 108 mg
DIM/day for 30 days showed a significant increase inTable 2 Comparison of initial and follow up measures of the
Lucentia Peak® and those patients who were untreated contr
Peak group 2-HE 16alpha-HE Ratio
Pre Mean 170.0 464.8 0.38
Pre SD 96.2 137.5 0.21
Post Mean 262.4 490.0 0.57
Post SD 117.7 173.0 0.27
p-value < 0.0001 0.1380 < 0.0001levels of 2-HE (P=0. 020) even though the limited sample
revealed a nonsignificant increase of 47% in the 2-OHE/
16alpha-OHE ratio (P=0.059) [24].
Studies of the other compounds in Lucentia Peak® also
have revealed potential anti-cancer effects mediated ei-
ther through hormonal effects or other physiological
processes. For example, resveratrol has been shown to
inhibit estrogen-DNA adduct formation via its antioxi-
dant function and to do so approximately 50% more
effectively than N-acetyl cysteine [25]. Icaritin, a prenyl
flavonoid derivative from Epimedium Genus has been
shown to induce cell cycle arrest in breast cancer cell
lines in vitro [19] and to have estrogenic effects in rat
studies [20]. Other compounds with estrogenic effects
such as red clover are frequently used by women with
breast cancer [26]. However, their effectiveness is not
established. Finally, several components in Lucentia Peak®
also may alter the expression of various inflammatory bio-
markers. Such anti-inflammatory properties might play an
important role in the potential anti-tumorogenesis effects
of this multi-nutrient supplement [11,13,21,22].
Limitations of this study include that it was a retro-
spective evaluation. Future randomized, prospective
and controlled trials will be necessary to better deter-
mine whether multi-nutrient supplements help reduce
the 2-HE/16alpha-HE ratio, and subsequently, the risk
of gynecological cancers. A placebo control would be
particularly important, especially in those patients with
low 2-HE/16alpha-HE ratios so that it can be more
clearly determined whether the supplement has a de-
finitive effect. Selection bias is a consideration since the
treated group generally had lower values for the 2-HE/
16alpha-HE ratio and therefore may have been given
more encouragement by their treating physician to utilize
the supplement for this purpose. However, it is noted that
the 2-HE/16alpha-HE ratios for the untreated group did
not change substantially.
Conclusions
Overall, this study showed that women with a low 2-HE/
16alpha-HE ratio who were given Lucentia Peak® experi-
enced an increase in the ratio, specifically related to an
increase in the measure of 2-HE. Given the potential re-
duction in the risk of gynecological cancer in patients2-HE/16alpha-HE ratio in those patients treated with
ol subjects
Control group 2-HE 16alpha-HE Ratio
Initial Mean 321.8 525.4 0.65
Initial SD 191.4 346.2 0.34
Follow up Mean 278.7 479.2 0.64
Follow up SD 131.1 174.6 0.33
0.301 0.290 0.474
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this study is an important step in evaluating a dietary
supplements that may have implications for women’s
preventive health.
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